Tech

The fires and resale realities of evolving EV market

Published

2 years ago

October 16, 2023

EVs face their fair share of challenges and concerns.

Concerns about battery fires in EVs have garnered significant attention from the media and the public. These fears have been fuelled by high-profile incidents, such as the car carrier fire off the Western Australia coast a few months ago and a car fire at Sydney airport in September. Media coverage has spiked, raising legitimate concerns about the safety of lithium-ion batteries commonly used in EVs.

Lithium-ion batteries, while compact and efficient, contain a vast amount of energy and undergo chemical-to-electrical energy conversions. However, faults or short circuits, often resulting from damage or excessive heat, can lead to a phenomenon known as thermal runaway. This can trigger a highly toxic, large-scale fire, challenging conventional extinguishing methods. Firefighters are now being trained to manage such incidents, and extensive research is being conducted to enhance safety measures.

Although EV fires are infrequent, their substantial coverage in the media has perpetuated a sense of fear and misinformation within the community. It is imperative to encourage a rational and data-driven approach to address these concerns, ensuring a balanced perspective on EV safety.

Moreover, apprehensions about battery longevity contribute to the skepticism surrounding used EVs. Buyers often hesitate to invest in used EVs, considering the battery’s health and performance over time.

To bolster the resale market for EVs, stakeholders in the industry are exploring potential solutions. One approach could involve policy adjustments, such as offering exemptions on Stamp Duty and three-year registration fees for purchasing used EVs. This could incentivise buyers and promote a thriving used EV market.

Tech

X restricts Grok AI as global backlash grows

X restricts Grok AI from creating sexualized images amid global backlash and regulatory concerns, aligning with UK guidelines.

Published

1 hour ago

January 15, 2026

Harvey Vargas

X restricts Grok AI from creating sexualized images amid global backlash and regulatory concerns, aligning with UK guidelines.

X has announced new restrictions on its Grok AI chatbot, preventing it from generating sexualized images of women amid mounting criticism and regulatory scrutiny worldwide.

The move comes after concerns over non-consensual image manipulation sparked widespread backlash from users, advocacy groups, and authorities.

UK Prime Minister Keir Starmer confirmed that the platform’s latest changes align with British law, as Ofcom launches a formal investigation to determine whether X has violated the Online Safety Act.

Regulators are closely monitoring the situation, highlighting growing global concerns about the ethical use of AI in image generation. Critics have argued that X’s initial measures were insufficient and did not adequately address the risks associated with sexualized AI content.

The controversy has also prompted action in Southeast Asia. Malaysia and Indonesia have blocked access to Grok entirely, citing the platform’s potential to generate inappropriate content.

Subscribe to never miss an episode of Ticker – https://www.youtube.com/@UCiMroZIXuwlSh1r5wZdeU6Q

#GrokAI #XPlatform #AIRegulation #OnlineSafety #KeirStarmer #AIControversy #TechNews #DigitalEthics

Tech

AI drives memory prices higher as SK hynix and TSMC expand

Explore the rising global memory market driven by AI demand and hear insights from Brad Gastwirth on industry trends.

Published

24 hours ago

January 14, 2026

Harvey Vargas

Explore the rising global memory market driven by AI demand and hear insights from Brad Gastwirth on industry trends.

The global memory market is on the rise, with prices climbing steadily thanks to booming AI infrastructure demand.

Companies like SK hynix and TSMC are investing heavily in advanced packaging and new facilities to meet this unprecedented growth.

We speak with Brad Gastwirth from Circular Technologies about the forces behind this upward momentum. From the difference between AI-driven and consumer-driven demand to the increasing memory requirements per AI system, Brad breaks down the trends shaping the industry.

We also explore the implications of lean DRAM and NAND inventories, disciplined supply growth, and the challenges of expanding packaging capacity versus wafer fabrication. Tune in to understand why incremental demand surprises can have a huge impact on memory pricing.

Subscribe to never miss an episode of Ticker – https://www.youtube.com/@weareticker

#AIMemory #SKHynix #TSMC #TechInvesting #MemoryMarket #AIInfrastructure #Semiconductors #TickerNews

Tech

Nvidia unveils AI that could transform gene editing and healthcare

Nvidia’s EDEN AI models for gene editing could revolutionize treatment of genetic diseases, enhancing DNA modifications amid healthcare advancements.

Published

1 day ago

January 14, 2026

Harvey Vargas

Nvidia’s EDEN AI models for gene editing could revolutionize treatment of genetic diseases, enhancing DNA modifications amid healthcare advancements.

Nvidia has introduced revolutionary AI models for programmable gene insertion at the J.P. Morgan Healthcare Conference.

The AI platform, EDEN, is designed to enhance DNA modifications and could pave the way for treatments of previously untreatable genetic diseases.

This initiative is part of Nvidia’s broader push into healthcare, including a $1 billion partnership with Eli Lilly to develop an AI-driven drug discovery lab. Early testing has shown promising results, with models designing proteins that precisely target disease-related sites in human cells.

While the breakthroughs are significant, experts caution that challenges remain in translating AI-generated therapies into real-world clinical applications. The future of medicine could be rewritten if these hurdles are overcome.

Subscribe to never miss an episode of Ticker – https://www.youtube.com/@weareticker

#NvidiaAI #GeneEditing #HealthcareInnovation #DNA #EDENPlatform #AIinMedicine #Biotech #DrugDiscovery